International AIDS Vaccine Initiative & Regeneron Pharmaceuticals

International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing rVSV Bundibugyo, a single-dose vaccine candidate seen as promising by the World Health Organization, though it is not yet ready for trials.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals developed maftivimab, an experimental treatment prioritized by the World Health Organization for the Bundibugyo strain of Ebola, with supplies already in the Democratic Republic of the Congo.

International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing a Bundibugyo-specific version of a vaccine using a platform similar to Merck & Co.'s Ervebo vaccine, contributing to the search for a treatment.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.